In a critical medical situation, time is everything. When a patient comes in with a life-threatening infection, a physician has a narrow window to figure out a course of antibiotic treatment, and with every second that passes, that window comes closer to slamming shut. Today, it can take a doctor between 2 to 5 days to diagnose an infection’s resistance to antibiotics, if they’re able to at all. A patient with sepsis can die in a matter of hours.
Day Zero Diagnostics is working to stem the tide of this public health crisis, combining genome sequencing, a large proprietary database, and machine learning to diagnose an infection’s antibiotic resistance profile within hours rather than days. With this information in hand, a doctor can treat a patient with a targeted antibiotic on the first day they are admitted to the hospital—day zero.
With a cause this important, the founding team at Day Zero Diagnostics needed a technology partner that would add real value and allow them to scale efficiently, without diverting key time or resources from their core mission. Shoobx was a natural fit.
“There are very few things we go to outside companies to do,” explains Day Zero CEO Jong Lee. “We’re very efficient about the way we use outside resources. When we approach a company like Shoobx, it’s because the technical skillset is critical.”
In 2016, Day Zero was a team of 5 that used Shoobx to sell $500,000 in convertible notes to friends and family. By 2019, the company had nearly quadrupled in size and had closed a $8.6 million Series A round to bring its total fundraise to $12 million. Here’s how Shoobx helped make that growth possible.